Loading stock data…
Rezolute (RZLT)
$5.10+0.06 (+1.19%)
After Hours$5.10+0.00 (+0.00%)· Last close Jun 29
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rezolute, Inc. in the Healthcare sector is trading at $5.10 with a market capitalization of $428M. Wall Street consensus targets $7.67 (9 analysts), implying a +50.3% move over the next 12 months. The stock is currently 55% below its 52-week high of $11.46, remaining 0.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.37M↑ | -$24.22M↓ | -$19.82M↑ | -$25.85M↓ | -$20.02M |
| Net Income | -$16.17M↑ | -$22.77M↓ | -$18.15M↑ | -$24.39M↓ | -$18.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$427.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.74%
Volume
Today's trading volume
1.32M
Recent News
Exploring 3 High Growth Tech Stocks in US Market
The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.
Positive Signs As Multiple Insiders Buy Rezolute Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Rezolute’s stock up on interim Phase III tumour HI data
Topline results for the fully enrolled open-label study are expected in the second half of 2026.